NCT06839664CompletedPhase 3
A Study of HS-20094 in Chinese Adults With Overweight or Obesity
A Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of HS-20094 in Overweight and Obese Subjects
Source: ClinicalTrials.gov · Last updated 8 Jun 2026
Brief summary (registry, in English)
The main purpose of this study is to assess the Efficacy and safety of HS-20094 in overweight and obese patients. The study will last up to approximately 52 weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 604 (actual)
- First submitted
- 18 Feb 2025
- Start date
- 16 Nov 2024
- Primary completion date
- 4 Jan 2026
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Diseases
- Obesity
- NCT number
- NCT06839664
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 604
- From 16 Nov 2024 to the primary completion date, 4 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Weight change \>5.0% after diet and exercise control for at least 12 weeks before screening
- Have used or are currently using weight loss drugs within 3 months before screening
Other illness
- Diabetes mellitus
- History of pancreatitis
- Family or personal history of medullary thyroid carcinoma(MTC)or multiple endocrine neoplasia syndrome type 2(MEN-2)
- History of moderate to severe depression, or have a history of serious mental illness
- Any lifetime history of a suicide attempt
- Have a history of significant atopy (severe allergic manifestations), multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions
- Have a history of any malignancy within the past 5 years
Who the study is looking for
- Male or female 18 to 65 years of age at the time of consent(cutoff value included).
- Body mass Index(BMI)≥28 kilograms per square meter(kg/m2),or ≥24 kg/m2 and previous diagnosis with at least one of the following comorbidities: prediabetes, hypertension, dyslipidemia, non-alcoholic fatty liver disease, obstructive sleep apnea.
- Weight change ≤5.0% after diet and exercise control for at least 12 weeks before screening.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.